Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Determining biomarkers of response to docetaxel for patients with metastatic castration-resistant prostate cancer using circulating cell-free tumour DNA
FY 2018-19
Summary
The primary chemotherapy for late-stage prostate cancer is only effective in 45% of patients. However, there is currently no way of knowing in advance which patients will benefit from treatment, and which patients could avoid the side-effects of chemotherapy and receive a different therapy instead. Herein lies an urgent clinical need for tests that can predict patient response to chemotherapy, thereby helping clinicians select the best cancer treatment for an individual patient.
My aim is to identify molecular markers capable of predicting whether a patient will respond to the chemotherapy docetaxel. My approach relies on the fact that cancerous tissues shed a small amount of their DNA into the bloodstream, creating an opportunity to examine the tumour by analyzing DNA isolated from a patient’s blood sample. This DNA, termed ‘circulating tumour DNA’ (ctDNA), provides a molecular snapshot of the tumor. CtDNA profiling is a novel technique that enables capture of information about a cancer via a blood test. This means that breakthroughs can be quickly translated to the clinic to inform treatment decisions.
To identify biomarkers predictive of docetaxel response, I have identified 74 eligible patients from a provincial biobank (established by my supervisors) of ctDNA samples from hundreds of metastatic patients. I will profile DNA from these patients using a custom bioinformatics approach, and will subsequently correlate findings to patient clinical history and treatment outcomes. Success with this project will help optimize treatment selection for patients with late-stage prostate cancer, resulting in improved quality and length of life for men with this aggressive disease.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
406339
Name
Herberts Cameron
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Determining biomarkers of response to docetaxel for patients with metastatic castration-resistant prostate cancer using circulating cell-free tumour DNA
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Genomics; Chemotherapy; Circulating-Tumour Dna; Genomic Biomarkers; Next-Generation Sequencing; Precision Oncology; Prostate Cancer
Abstract
The primary chemotherapy for late-stage prostate cancer is only effective in 45% of patients. However, there is currently no way of knowing in advance which patients will benefit from treatment, and which patients could avoid the side-effects of chemotherapy and receive a different therapy instead. Herein lies an urgent clinical need for tests that can predict patient response to chemotherapy, thereby helping clinicians select the best cancer treatment for an individual patient.
My aim is to identify molecular markers capable of predicting whether a patient will respond to the chemotherapy docetaxel. My approach relies on the fact that cancerous tissues shed a small amount of their DNA into the bloodstream, creating an opportunity to examine the tumour by analyzing DNA isolated from a patient’s blood sample. This DNA, termed ‘circulating tumour DNA’ (ctDNA), provides a molecular snapshot of the tumor. CtDNA profiling is a novel technique that enables capture of information about a cancer via a blood test. This means that breakthroughs can be quickly translated to the clinic to inform treatment decisions.
To identify biomarkers predictive of docetaxel response, I have identified 74 eligible patients from a provincial biobank (established by my supervisors) of ctDNA samples from hundreds of metastatic patients. I will profile DNA from these patients using a custom bioinformatics approach, and will subsequently correlate findings to patient clinical history and treatment outcomes. Success with this project will help optimize treatment selection for patients with late-stage prostate cancer, resulting in improved quality and length of life for men with this aggressive disease.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Herberts, Cameron
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~